aptamer ͉ multiple sclerosis M idkine (MK), a heparin-binding growth factor, exerts pleiotropic effects, including cell proliferation, cell migration, angiogenesis, and fibrinolysis, in a variety of tissues (1) . MK also plays important roles in the induction of oncogenesis, inflammation, and tissue repair. The overexpression of MK has been observed in a number of malignant tumors (1) . However, MKdeficient mice are reportedly resistant to ischemic renal injury (2) and neointima formation in atherosclerosis (3) . A recent study proposed that MK deficiency suppresses the development of a rheumatoid arthritis model by preventing inflammatory leukocyte migration and osteoclast differentiation (4) . Furthermore, MK expression is up-regulated in the spinal cord during the induction and progression phases of experimental autoimmune encephalomyelitis (EAE) (5) . However, the precise immunological functions of MK have yet to be elucidated.
Multiple sclerosis (MS) and its animal model, EAE, are autoimmune diseases characterized by inflammatory demyelination in the CNS (6) . Although MS and EAE have been described as T-helper type 1 (T H 1) cell-mediated autoimmune diseases, T H 17 cells, a newly discovered lineage of CD4 ϩ T cells that secrete IL-17, have recently been found to be critical for the development of autoimmune diseases, including EAE (7) (8) (9) (10) . Various types of immune cells and soluble mediators contribute to the complex mechanism underlying the onset and progression of MS, which is characterized by autoreactive T cell infiltration and the activation of microglia, the resident antigen-presenting cells in the CNS. In particular, CD4 ϩ CD25 ϩ regulatory T (Treg) cells have received a great deal of attention as negative regulators of MS pathogenesis (11) (12) (13) (14) . Treg cells regulate peripheral tolerance and autoimmunity, and abnormalities in Treg cell function may contribute to the development of autoimmune diseases (15) (16) (17) . Thus, expansion of the Treg cell population could prevent autoimmune attacks, including EAE (12-14, 18, 19) .
Here, we show that MK deficiency attenuates myelin oligodendrocyte glycoprotein (MOG)-induced EAE due to an expansion of the Treg cell population in the peripheral lymph nodes, followed by decreases in the numbers of autoreactive T H 1 and T H 17 cells. Moreover, administration of anti-MK RNA aptamers that effectively neutralize MK induced expansion of the Treg cell population and reduced the symptoms of EAE. This demonstrates that MK is a critical suppressor of Treg cell expansion. Moreover, inhibition of MK using RNA aptamers may be a potent therapeutic strategy against autoimmune diseases, including MS.
Results

MK Deficiency
Attenuates MOG-Induced EAE. To examine the immunological roles of MK, we generated MOG -induced EAE in C57BL/6J WT and MK-deficient (Mdk Ϫ/Ϫ ) mice. Most of the WT mice exhibited clinical signs of the disease Ϸ12 days after the initial immunization and developed peak EAE Ϸ18 days after immunization as described previously (20, 21) . Almost all of the Mdk Ϫ/Ϫ mice also developed EAE. However, the clinical scores of the Mdk Ϫ/Ϫ mice were significantly lower than those of the WT mice (Fig. 1a) .
To confirm whether the suppression of EAE in the Mdk Ϫ/Ϫ mice was due to MK deficiency, we administrated MK to the Mdk Ϫ/Ϫ mice with s.c.-implanted microosmotic pumps for Ϸ16 days after MOG immunization as described previously (3, 4) . As shown in Fig.  1 , MK administration to Mdk Ϫ/Ϫ mice abolished the suppression of EAE (Mdk Ϫ/Ϫ ϩ MK) (Fig. 1a) . However, the cessation of MK administration resulted in regaining the attenuation of EAE in Mdk Ϫ/Ϫ ϩ MK mice (starting 22 days after MOG immunization).
Histological analysis of the lumbar spinal cord revealed that Mdk Ϫ/Ϫ -EAE mice had fewer infiltrating inflammatory cells than WT-EAE mice (WT mice) ( Fig. 1 b and e) (Mdk Ϫ/Ϫ mice) ( Fig. 1  c and f ) . MK administration also reversed this reduced level of CNS inflammation in the Mdk Ϫ/Ϫ mice (Mdk Ϫ/Ϫ ϩ MK mice) ( Fig. 1 d  and g ). These histological findings agreed with the clinical data.
Taken together, these data indicate that MK plays an important role in the induction and development of EAE and that these immunological effects of MK are transient and reversible. , and iNOS in microglia or macrophages (as the antigen-presenting cells in the CNS or periphery, respectively). Before stimulation with LPS and IFN-␥, Mdk Ϫ/Ϫ microglia had higher B7-2, MCP-1, and IL-1␤ expression levels and lower ICAM-1 and MIP-1␣ expression levels than WT microglia. In contrast, Mdk Ϫ/Ϫ macrophages had higher B7-1 and B7-2 expression levels than WT macrophages. After stimulation with LPS and IFN-␥, however, these differences were no longer observed, except for decreased expression of VCAM-1 and MIP-1␣ in Mdk Ϫ/Ϫ microglia [supporting information (SI) Fig. 6a ]. The total number of mononuclear cells from the peripheral lymph nodes was similar between WT and Mdk Ϫ/Ϫ mice (data not shown). Thus, we assessed subpopulations of T cells in the peripheral lymph nodes. No significant differences were found between WT and Mdk Ϫ/Ϫ mice in the CD4 ϩ and CD8 ϩ T cell populations (SI Fig. 6 b-d) . Interestingly, however, the CD4 ϩ CD25 ϩ T cell populations had undergone a significant expansion in the Mdk Ϫ/Ϫ -EAE mice, compared with those in the WT-EAE mice ( Fig. 2 a and b) . This 
difference of CD4
ϩ CD25 ϩ T cell populations was not detected between WT and Mdk Ϫ/Ϫ mice without immunization (data not shown). This T cell subpopulation was found to express TGF-␤, IL-10, and forkhead box protein P3 (Foxp3) ( Fig. 2 c and d) , and it suppressed the antigen-specific expansion of the CD4 ϩ CD25
Ϫ T cell population in a titer-dependent manner (Fig. 2e) . Thus, these cells were identified as CD4 ϩ CD25 ϩ Foxp3 ϩ Treg cells. Depletion of Treg cells from Mdk Ϫ/Ϫ mice via the administration of anti-CD25 monoclonal antibodies abolished the suppression to EAE in these mice ( Fig. 2f and SI Fig. 7 ). Moreover, MK administration in Mdk Ϫ/Ϫ mice markedly inhibited the increase in the number of Treg cells and the corresponding increase in Foxp3 expression ( Fig. 3 a  and b ). These findings demonstrated that MK deficiency transiently recruits an expanded population of Treg cells to the peripheral lymph nodes after MOG immunization, and this expansion of the Treg population may contribute to the attenuation of EAE.
To clarify whether MK affected the Treg cell population expansion directly, we assessed the antigen-specific expansion of the Treg cells ex vivo. Splenic CD4 ϩ T cells isolated from WT mice at peak MOG-EAE were stimulated with MOG peptide for 3 days in vitro. MK administration significantly decreased the Treg cell percentage and the Foxp3 expression level in a dose-dependent manner ( Fig.  3 c and d) . STAT5 was recently demonstrated to be essential for Foxp3 expression and critical for both CD4 ϩ CD25 ϩ Treg cell development and maintenance (22, 23) . As shown in Fig. 3e , MK diminished the phosphorylation of STAT5 in a dose-dependent manner. Because STAT3 is reported to be critical for IL-6-dependent attenuation of Foxp3 expression (23), we assessed whether MK affects STAT3 phosphorylation. However, MK did not affect STAT3 phosphorylation in CD4 ϩ CD25 ϩ cells (data not shown). Recent studies revealed that tyrosine phosphatase SHP-2 is a critical suppressor of STAT5 (24) . MK enhanced the expression of SHP-2, and the inhibition of SHP-2 restored STAT5 phosphorylation and subsequent Foxp3 expression suppressed by MK (Fig.  3 f and g ). These data indicate that MK deficiency contributes to the expansion of the Treg cell population through the dephosphorylation of STAT5 by SHP-2.
Because EAE is a T H 1 and/or T H 17 cell-mediated autoimmune disease, we next examined whether the resistance to EAE in the Mdk Ϫ/Ϫ mice was associated with the suppression of autoreactive T H 1 and T H 17 cell populations in the periphery and CNS. As shown in Fig. 4 , significantly lower amounts of IFN-␥ and IL-17 were produced in the MOG-specific CD4 ϩ T cells from the Mdk Ϫ/Ϫ -EAE mice than in those cells from the WT-EAE mice (P Ͻ 0.05). In contrast, the MOG-specific CD4 ϩ T cells from the Mdk Ϫ/Ϫ -EAE mice did not produce a detectable amount of the T H 2 cytokine IL-4, as was not observed for WT-EAE mice (data not shown). These data indicate that the autoreactive T H 1 and T H 17 cell populations were suppressed in the Mdk Ϫ/Ϫ -EAE mice, but not in the WT-EAE mice. Therefore, we believe that MK serves as a critical suppressor of Treg cell expansion, and MK deficiency ameliorates EAE by expanding the population of Treg cells, which correspondingly suppresses the autoreactive T H 1 and T H 17 cell populations.
RNA Aptamer-Based Inhibition of MK Effectively Suppresses EAE. We next attempted to develop a therapeutic approach to treat EAE/MS using RNA aptamers that blocked MK function. Aptamer-based therapies have recently attracted attention as alternatives to antibody therapies (25) (26) (27) . The anti-MK RNA aptamer used in this study was a 49-mer that was stabilized with ribose-2Ј modifications, as well as cholesterol and inverted dT tags at its 5Ј and 3Ј ends, respectively (S.M., M.F., and Y.N., unpublished data). The apparent dissociation constant (K d ) estimated from the surface plasmon resonance (SPR) profile was 0.9 nM (Fig. 5a ). RNA aptamers have been reported to overcome several disadvantages associated with therapeutic antibodies, such as neutralization, batch-to-batch variation, production limitations, and total cost. As expected, the administration of anti-MK RNA aptamers induced expansion of the Treg cell population and reduced the mean EAE clinical score in a dose-dependent manner (Fig. 5 b and c) . Moreover, the aptamers administered after EAE onset also diminished the EAE clinical score (Fig. 5d) . The results suggest that aptamer-based inhibition of MK is an alternative to therapeutic antibodies for the treatment of autoimmune diseases, such as MS.
Discussion
The present study demonstrates that MK is a critical suppressor of Treg cell expansion. We have shown that MK deficiency reduces the severity of EAE through an expansion of the Treg population in peripheral lymph nodes, followed by decreases in the numbers of autoreactive T H 1 and T H 17 cells. MK signaling is mediated by MK receptors, including protein-tyrosine phosphatase , low-density lipoprotein receptor-related protein, anaplastic leukemia kinase, and syndecan-3 (1). Downstream signaling of MK activates the PI3K, PKC, and MAPK MEK1/2 pathways. These signaling pathways are thought to be associated with various functions that involve MK, including inflammatory cell migration and activation. MK is up-regulated in inflammatory cells, including activated macrophages, neutrophils, and T cells (1-4, 28) . Thus, recent studies have proposed that the antiinflammatory condition resulting from MK deficiency was due to the loss of cytokine/chemokine-mediated migration signals directed at inflammatory cells (2) (3) (4) . In the present study, however, we have revealed that loss of MK signaling attenuates EAE mainly via expansion of the Treg cell population because Treg cell depletion using anti-CD25 monoclonal antibodies completely cancelled the suppression of EAE in Mdk Ϫ/Ϫ mice. Moreover, we demonstrated that MK reduces the expansion of the Treg cell population ex vivo. A previous report showed that MK expression is up-regulated in the spinal cord during the induction and progression phases of EAE and then returns to a normal level during the recovery phase (5). However, an increased number of Treg cells is reportedly associated with recovery from EAE (29, 30) . Taken together, these results suggest that MK participates in the induction and progression of EAE through the suppression of the Treg cell population.
Treg cells are believed to play a pivotal role in immunological homeostasis, and the suppression and/or dysregulation of Treg cells can induce autoimmune and inflammatory disorders, such as MS (11-13, 15, 18, 19) . Recent studies showed that STAT5 is essential for IL-2-dependent Foxp3 expression and critical for both Treg cell development and maintenance (22, 23) . STAT3 also is documented to be critical for IL-6-dependent attenuation of Foxp3 expression (23) . Thus, STAT5 and STAT3 are considered to have opposing roles in regulating Foxp3; however, the factors that regulate Treg cells are still largely unknown. In this study, we demonstrated that MK decreases Treg cell population by the suppression of IL-2-dependent STAT5 phosphorylation and Foxp3 expression through the up-regulation of SHP-2 (SI Fig. 8 ), whereas MK did not alter STAT3 phosphorylation. Although MK signaling participates in the PI3K, PKC, and MAPK MEK1/2 pathways, we were not able to identify which pathway enhances SHP-2 (data not shown). Further investigation is needed to elucidate the detailed molecular mechanism of this process.
Recent studies have revealed that estrogen (31-34), vasoactive intestinal peptide (VIP) (35, 36) , and CD28 superagonist (37) (38) (39) induce the expansion of the Treg cell population. Although administration of estrogen, VIP, or CD28 superagonist could potentially relieve autoimmune diseases by increasing Treg cell numbers, these molecules are associated with a number of adverse effects that must be considered (estrogen: feminization, thrombosis, and oncogenesis; VIP: watery diarrhea, hypokalemia, and achlorhydria; CD28 superagonist: cytokine storm syndrome leading to fatality). MK deficiency, in contrast, does not result in any significant adverse abnormalities or symptoms (1) .
In this study, we inhibited MK activity with anti-MK RNA aptamers. Aptamers are single-stranded oligonucleotides synthesized in vitro using an RNA selection-amplification protocol referred to as systematic evolution of ligands by exponential amplification (SELEX) (25) (26) (27) . Aptamers are isolated from randomized RNA libraries as high-affinity oligonucleotides that recognize a wide range of target molecules with affinities and specificities that are comparable to those of antibodies. Although antibody therapy is a potent therapeutic strategy, the characteristics of RNA aptamers circumvent several disadvantages associated with therapeutic antibodies. First, unlike therapeutic antibodies, aptamers do not trigger an immune response that could neutralize the introduced molecules. Second, the process by which aptamers are chemically synthesized allows large amounts of aptamers to be produced without batch-to-batch variations. Third, aptamers are amenable to various chemical modifications, including organ-targeting signals. Fourth, the chemical synthesis process can reduce total production cost of aptamers, compared with that of therapeutic antibodies. Therefore, aptamer-based therapy is a potent therapeutic strategy that may replace many antibody therapies in the future. Recently, the U.S. Food and Drug Aministration approved antivascular endothelial growth factor aptamer as the treatment for age-related macular degeneration (40) . Our study also provides strong evidence for the clinical efficacy of RNA aptamers.
Methods
Reagents. MOG peptide 35-55 (MOG35-55; MEVGWYRSPFSRVVHLYRNGK) was synthesized and purified by Operon Biotechnologies. Incomplete Freund's adjuvant was obtained from Sigma-Aldrich. Heat-killed Mycobacterium tuberculosis H37Ra was obtained from Difco, and pertussis toxin was obtained from List Biological Laboratories. Anti-MK RNA aptamers were developed by Ribomic essentially as described previously (41) . In brief, RNA aptamers were raised against MK by sing SELEX. The functionally optimized 49-mer RNA was modified with fluorine and O-methyl at the 2Ј position of each ribose and with a cholesterol moiety and inverted dT tags at the 5Ј and 3Ј ends, respectively (S.M., M.F., and Y.N., unpublished data). The RNA administered to the animals was chemically synthesized (Gene Design). The antibodies used are as follows: PE-Cy5-antimouse CD4 (GK1.5; BD Pharmingen), PE-anti mouse CD8 (53-6.7; BD Pharmingen), PE-anti-mouse CD11b (M1/70; BD Pharmingen), PE-anti-mouse CD25 (PC61 or 7D4; BD Pharmingen), FITC-anti-mouse CD40 (HM40 -3; BD Pharmingen), PE-anti-mouse B7-1 (CD80, 16 -10A1; BD Pharmingen), FITC-anti-mouse B7-2 (CD86, GL-1; BD Pharmingen), anti-mouse-MHC Class II I-A/I-E (2G9; BD Pharmingen), FITC-anti-mouse Foxp3 (FJK-16s; eBiosciences), PE-anti-phospho-STAT3 (pY705), and PE-anti-phospho-STAT5 (pY694) (BD Pharmingen) anti-mouse SHP-2 antibody (Cell Signaling).
SPR Analysis. The SPR assays were performed essentially as described previously (42) using a Biacore 2000 instrument, except that MK was immobilized on a CM4 sensor chip via amino coupling (Ϸ1,000 RUs). Curves closely fit to the sensorgrams were calculated as global fitting curves (1:1 Langmuir binding) generated by using the BIAevaluation 3.0 software (Biacore to estimate the Kd value).
Animals. The protocols for animal experiments were approved by the Animal Experiment Committee of Nagoya University. C57BL/6J mice deficient for the MK gene (Mdk) were generated as described previously (43) . After backcrossing Mdk ϩ/Ϫ mice to C57BL/6J mice for Ͼ10 generations, Mdk ϩ/Ϫ mice were mated with each other to generate Mdk ϩ/ϩ and Mdk Ϫ/Ϫ mice, which were used in the present study. All experiments were performed with Mdk ϩ/ϩ and Mdk Ϫ/Ϫ littermates.
Active Induction of MOG-EAE. MOG-EAE mice were produced and assessed as described previously (20) .
MK Administration with an s.c.-Implanted Microosmotic Pump. We administrated MK to mice with s.c.-implanted microosmotic pumps as described previously (3). Briefly, MK dissolved in PBS at a concentration of 1 mg/ml was loaded into a microosmotic pump (model 1002; Durect), which released 0.25 l of the solution per hour of MK for 14 days. A pump containing PBS (vehicle control) or MK (treated group) was implanted s.c. under anesthesia on the day of immunization. For some experiments, mice underwent sham operations (operated control) and were used instead of the vehicle control mice.
In Vivo Depletion of Treg Cells. To deplete the Treg cell population in vivo, mice were i.p. injected with 250 g of purified anti-CD25 monoclonal antibodies (PC61) as described previously (44, 45) . Control animals received PBS or rat IgG (Jackson ImmunoResearch). Four days later, peripheral blood mononuclear cells or splenocytes were analyzed for the lack of CD4 ϩ CD25 ϩ T cells after labeling the cells with anti-CD4 and anti-CD25 monoclonal antibodies (7D4), which bind to CD25 noncompetitively with PC61.
Administration of anti-MK Neutralizing anti-MK RNA Aptamers. Mice were i.p. injected with the indicated doses of anti-MK RNA aptamers every other day from the day of MOG immunization or EAE onset (Ϸ14 days after immunization).
Histological Analysis. Mice with peak EAE were anesthetized and perfused transcardially with 4% paraformaldehyde (PFA) in 0.1 M PBS. Lumbosacral spinal cords were immediately removed, postfixed in 4% PFA, and embedded in paraffin. Five-micrometer-thick sections were stained with H&E by using standard procedures. Stained sections were observed under a microscope.
In Vitro Priming of MOG-Specific CD4 ؉ T Cells. Mononuclear cells were collected from the spleen and CNS as described previously (46) . CD4 ϩ or CD4 ϩ CD25 ϩ T cells were purified with magnetic cell sorting according to the manufacturer's protocols (Miltenyi Biotec). The purities of the CD4 ϩ and CD4 ϩ CD25 ϩ T cell samples were Ͼ97% as determined by CD4-or CD25-specific immunostaining. Purified CD4 ϩ T cells (2 ϫ 10 5 cells per well) isolated from the spleens or CNS of peak EAE mice were cultured with mitomycin C-treated feeder cells (5 ϫ 10 6 cells per well) in the presence of 20 ng/ml MOG35-55 for 1, 3, and 5 days. The concentrations of IL-17, IFN-␥, and IL-4 in the culture supernatant were assessed by using the corresponding cytokine-specific ELISA kits (IL-17, R & D Systems; IFN-␥ and IL-4, BD Pharmingen) as described previously (20) . To examine the effect of MK on the Treg cell population, cells stimulated with 20 ng/ml MOG35-55 for 3 days in the presence of 0, 20, or 100 ng/ml MK were analyzed by flow cytometry. To evaluate T cell proliferation, purified CD4 ϩ CD25 ϩ T cells isolated from the spleens of peak EAE mice were cultured at different ratios (0.1:1, 0.3:1, and 1:1) with CD4 ϩ CD25 Ϫ T cells in the presence of mitomycin C-treated feeder cells (5 ϫ 10 6 cells per well) and 20 ng/ml MOG35-55 for 3 days. T cell proliferation was assessed by using a mouse IL-2 ELISA kit (BD Pharmingen) as described previously (20) .
Flow Cytometry. Cells were isolated from spleens, mesenteric lymph nodes, and popliteal lymph nodes. RBCs were removed from the samples with lysis buffer (Dako). To evaluate the phosphorylation of STATs, cells were pretreated with each inhibitor (MEK1/2 inhibitor PD98059, PI3K inhibitor wortmannin, PKC inhibitor staurosporin, or SHP-2 inhibitor; Calbiochem) for 3 h. Cells were subsequently incubated with 100 ng/ml MK for 15 min, followed by a 5-min treatment of 20 ng/ml IL-2. Then cells were collected in Cytefix/Cyteperm (BD Pharmingen) containing phosphatase inhibitor mixture (Sigma-Aldrich). To prevent nonspecific binding, cells were incubated with anti-mouse Fc␥ III/II receptor monoclonal antibodies (2.4G2; BD Pharmingen) at 4°C for 30 min. Then cells were labeled with the specific antibodies for 30 min at 4°C, followed by analysis with a flow cytometer (Cytomics FC500; Beckman Coulter) as described (21) .
Western Blotting. Cells were lysed in TNES buffer [50 mM Tris⅐HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 2 mM EDTA, and 0.1% SDS] with a protease inhibitor mixture (Roche Diagnostics) and a phosphatase inhibitor mixture (SigmaAldrich); 10 g of protein from the total lysate was examined for Western blot analysis as described (47) .
Analysis of Microglia and Macrophages.
Mouse primary microglia were isolated from primary mixed glial cell cultures, which were obtained from newborn mice using the shaking-off method described previously in ref. 48 . Peritoneal macro-phages were prepared from mice that had received an i.p. injection of thioglycolate 72 h before collection. Macrophages were cultured in the same medium as the microglia. Microglia and peritoneal macrophages (1 ϫ 10 6 cells per ml) were cultured in 24-well plates with or without 1 g/ml LPS plus 1 ng/ml IFN-␥ for 24 h in the presence of 250 ng/ml MK. Total RNA was extracted from the cells by using an RNeasy Mini-Kit according to the manufacturer's protocol (Qiagen). Firststrand cDNA was generated from 5 g of total RNA by using SuperScript II (Invitrogen). mRNA expression of antigen-presenting molecules (MHC class II, B7-1, B7-2, ICAM-1, and VCAM-1), cytokines (TNF-␣, IL-1␤, IL-6, IL-12p40, and IL-12p35), chemokines (IP-10, RANTES, MIP-1␣, and MCP-1), and iNOS was assessed by using semiquantitative PCRs as described (49) . All experiments were carried out in six independent trials.
Real-Time RT-PCR Analysis of Foxp3 Expression. Real-time RT-PCR analysis was carried out by using an ABI Prism 7000 sequence detection system (Applied Biosystems) as described previously (50) . The relative expression levels of Foxp3 were determined by normalization to the GAPDH expression level. The primer sequences used were as follows: Foxp3 forward, 5Ј-TTCATGCATCAGCTCTCCAC-3Ј; Foxp3 reverse, 5Ј-CTGGACACCCATTCCAGACT-3Ј; GAPDH forward, 5Ј-ACTCACGGCAAATTCAACG-3Ј; and GAPDH reverse, 5Ј-CCCTGTTGCTGTAGC-CGTA-3Ј. All experiments were carried out in six independent trials. Statistical Analysis. The data were analyzed with Statview software version 5 (SAS Institute) using unpaired Student's t tests or one-way ANOVA with a TukeyKramer post hoc test.
